Biogen, Inc. (BIIB)
216.78
-1.72
(-0.79%)
USD |
NASDAQ |
Aug 31, 16:00
216.78
0.00 (0.00%)
After-Hours: 20:00
Biogen Research and Development Expense (Annual) : 1.481B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.481B |
| December 31, 2024 | 1.755B |
| December 31, 2023 | 2.208B |
| December 31, 2022 | 1.959B |
| December 31, 2021 | 2.266B |
| December 31, 2020 | 3.789B |
| December 31, 2019 | 2.09B |
| December 31, 2018 | 2.597B |
| December 31, 2017 | 2.254B |
| December 31, 2016 | 1.973B |
| December 31, 2015 | 2.013B |
| December 31, 2014 | 1.893B |
| December 31, 2013 | 1.444B |
| December 31, 2012 | 1.335B |
| December 31, 2011 | 1.220B |
| Date | Value |
|---|---|
| December 31, 2010 | 1.249B |
| December 31, 2009 | 1.283B |
| December 31, 2008 | 1.072B |
| December 31, 2007 | 925.16M |
| December 31, 2006 | 718.39M |
| December 31, 2005 | 747.67M |
| December 31, 2004 | 687.66M |
| December 31, 2003 | 233.34M |
| December 31, 2002 | 93.65M |
| December 31, 2001 | 86.30M |
| December 31, 2000 | 68.92M |
| December 31, 1999 | 42.83M |
| December 31, 1998 | 31.48M |
| December 31, 1997 | 28.40M |
| December 31, 1996 | 24.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ionis Pharmaceuticals, Inc. | 913.18M |
| AbbVie, Inc. | 8.249B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Amgen, Inc. | 6.974B |